Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Assistenzarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
2023 SS
Vergangene Veranstaltungen (max. 10)
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
-
2020 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
BRAF inhibitor cessation prior to disease progression in metastatic melanoma : Long-term outcomesIn: European Journal of Cancer (EJC) Jg. 179 (2023) S. 87 - 97ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 4,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC) Jg. 183 (2023) S. 1 - 10ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 181 (2023) S. 188 - 197ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapyIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 3,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
The Latest Option: Nivolumab and Relatlimab in Advanced MelanomaIn: Current Oncology Reports (2023) in pressISSN: 1534-6269; 1523-3790Online Volltext: dx.doi.org/ (Open Access)
-
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas : A retrospective cohort study from five European skin cancer reference centresIn: Journal of the European Academy of Dermatology and Venereology (2023)ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ (Open Access)
-
Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary SyndromeIn: International Journal of Radiation Oncology, Biology, Physics (2023)ISSN: 1879-355X; 0360-3016Online Volltext: dx.doi.org/
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet Jg. 400 (2022) Nr. 10358, S. 1117 - 1129ISSN: 1474-547X; 0140-6736; 0023-7507Online Volltext: dx.doi.org/
-
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment : A prospective singlecenter study investigating seroconversion ratesIn: Frontiers in Oncology Jg. 12 (2022)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 - 44ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ (Open Access)
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine Jg. 12 (2022) Nr. 11,ISSN: 2001-1326Online Volltext: dx.doi.org/ (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research Jg. 35 (2022) Nr. 6, S. 573 - 586ISSN: 1755-1471; 1755-148XOnline Volltext: dx.doi.org/ (Open Access)
-
Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions : Non-interventional Cohort Study JONASIn: Acta Dermato-Venereologica Jg. 102 (2022)ISSN: 1651-2057; 0001-5555; 0365-8341Online Volltext: dx.doi.org/ (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers Jg. 14 (2022) Nr. 9,ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers Jg. 14 (2022) Nr. 17,ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer (2022) in pressISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC) Jg. 166 (2022) S. 60 - 72ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Guideline-Based Context-Sensitive Decision Modeling for Melanoma PatientsIn: Studies in Health Technology and Informatics Jg. 296 (2022) S. 50 - 57ISSN: 1879-8365; 0926-9630Online Volltext: dx.doi.org/ (Open Access)
-
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 6,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Low‐dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T‐cell lymphomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. 3, S. 279 - 285ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1, S. 29 - 34ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging Jg. 22 (2022) Nr. 1,ISSN: 1470-7330; 1740-5025Online Volltext: dx.doi.org/ (Open Access)
-
Niedrig dosierte Ganzhautelektronenbestrahlung mit oraler Bexaroten-Erhaltungstherapie beim kutanen T-Zell-LymphomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. 3, S. 279 - 286ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Quality of life in patients with mycosis fungoides and Sézary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapyIn: Journal of the American Academy of Dermatology: JAAD Jg. 86 (2022) Nr. 4, S. 889 - 891ISSN: 1097-6787; 0190-9622Online Volltext: dx.doi.org/
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 3, S. 396 - 398ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC) Jg. 161 (2022) S. 99 - 107ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyIn: European Heart Journal Jg. 43 (2022) Nr. 4, S. 316 - 329ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS) Jg. 23 (2022) Nr. 6,ISSN: 1422-0067; 1661-6596Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Validating Automatic Concept-Based Explanations for AI-Based Digital HistopathologyIn: Sensors Jg. 22 (2022) Nr. 14,ISSN: 1424-8220Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Allosteric and ATP-competitive MEK-inhibition in a novel spitzoid melanoma model with a raf-and phosphorylation-independent mutationIn: Cancers Jg. 13 (2021) Nr. 4, S. 829ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology Jg. 11 (2021)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Case Report : Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant MelanomaIn: Frontiers in Oncology Jg. 11 (2021) S. 637185ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) Jg. 152 (2021) S. 139 - 154ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer : A retrospective analysis of 47 casesIn: European Journal of Cancer (EJC) Jg. 150 (2021) S. 119 - 129ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapyIn: eNeurologicalSci Jg. 22 (2021) S. 100324ISSN: 2405-6502Online Volltext: dx.doi.org/ (Open Access)
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology Jg. 11 (2021)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Discontinuation of braf/mek-directed targeted therapy after complete remission of metastatic melanoma : a retrospective multicenter adoreg studyIn: Cancers Jg. 13 (2021) Nr. 10, S. 2312ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
48th Annual Scientific Meeting Cancer care and research: Learning from the past and improving the future, 16-18 November 2021,In: Asia-Pacific Journal of Clinical Oncology Jg. 17 (2021) Nr. 9, SI, S. 162 - 163ISSN: 1743-7555; 1743-7563Online Volltext: dx.doi.org/ (Open Access) -
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV⁶⁰⁰ mutant melanoma : safety and tolerability results from the phase I IMMU-TARGET trialIn: The European Journal of Cancer Jg. 158 (2021) S. 72 - 84ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers Jg. 13 (2021) Nr. 10, S. 2319ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapyIn: ESMO Open Jg. 6 (2021) Nr. 5,ISSN: 2059-7029Online Volltext: dx.doi.org/ (Open Access)
-
Kutanes Angiosarkom mit klinischem Bild eines Quincke-ÖdemsIn: Der Hautarzt Jg. 72 (2021) Nr. 9, S. 801 - 804ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ (Open Access)
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 395 - 404ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Long-term Quality of Life in Patients with Mycosis fungoides and Sezary Syndrome after low-dose Total Skin Electron Irradiation : Prospective StudyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 57 - S58ISSN: 1439-099X; 0179-7158
-
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. 8, S. 1217 - 1219ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer Jg. 148 (2021) S. 340 - 347ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) Jg. 159 (2021) S. 113 - 124ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 61 - 75ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 6, S. 1763 - 1771ISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibIn: Clinical Cancer Research Jg. 27 (2021) Nr. 16, S. 4500 - 4510ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ (Open Access)
-
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC) Jg. 143 (2021) S. 43 - 45ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 37 - 48ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsIn: European Journal of Cancer (EJC) Jg. 155 (2021) S. 268 - 280ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : a randomised, double-blind, placebo-controlled, phase 2 trialIn: The Lancet Jg. 395 (2020) Nr. 10236, S. 1558 - 1568ISSN: 1474-547X; 0140-6736Online Volltext: dx.doi.org/
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 26 (2020) Nr. 7, S. 1147ISSN: 1546-170X; 1078-8956Online Volltext: dx.doi.org/ (Open Access)
-
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer Jg. 131 (2020) S. 18 - 26ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology Jg. 10 (2020) S. 592609ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
ECG Changes in Melanoma Patients Undergoing Cancer Therapy : Data from the ECoR RegistryIn: Journal of Clinical Medicine (JCM) Jg. 9 (2020) Nr. 7,ISSN: 2077-0383Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Jg. 31 (2020) Nr. 1, S. 144 - 152ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 10, S. 1165 - 1168ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD Jg. 183 (2020) Nr. 5, S. 928 - 939ISSN: 1365-2133; 0007-0963; 0366-2845Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy : A retrospective multicenter DeCOG study of 84 patientsIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 2, S. e000897ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist Jg. 61 (2020) Nr. 7, S. 669 - 675ISSN: 1432-1289; 0020-9554Online Volltext: dx.doi.org/ (Open Access)
-
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma : A multicenter retrospective cohort study of the DeCOGIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1, S. e000395ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 8, S. 713 - 720ISSN: 1433-0415; 0947-8965Online Volltext: dx.doi.org/
-
Malignes MelanomIn: Der Hautarzt Jg. 71 (2020) S. 63 - 77ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/
-
Malignes MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 1, S. 75 - 87ISSN: 0947-8965; 1433-0415Online Volltext: dx.doi.org/
-
Malignes MelanomIn: Der Pathologe Jg. 41 (2020) Nr. 3, S. 281 - 292ISSN: 0172-8113Online Volltext: dx.doi.org/
-
Survival of patients with advanced metastatic melanoma : The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019In: European Journal of Cancer Jg. 130 (2020) S. 126 - 138ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma : A multi-institutional retrospective studyIn: The Journal of Dermatology Jg. 47 (2020) Nr. 6, S. 629 - 635ISSN: 1346-8138; 0385-2407Online Volltext: dx.doi.org/
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer Jg. 119 (2019) S. 66 - 76ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases : a real-life multicenter studyIn: Melanoma Research Jg. 29 (2019) Nr. 1, S. 65 - 69ISSN: 0960-8931; 1473-5636Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of cutaneous adverse events of encorafenib and binimetinb : COMMENT on article by Graf et al.In: Journal of the European Academy of Dermatology and Venereology Jg. 33 (2019) Nr. 4, S. 630 - 631ISSN: 1468-3083; 0926-9959Online Volltext: dx.doi.org/ (Open Access)
-
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 5, S. 765 - 772ISSN: 1432-0851; 0340-7004Online Volltext: dx.doi.org/
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. Suppl. 5, S. 7 - 7ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaIn: European Journal of Cancer Jg. 119 (2019) S. 18 - 29ISSN: 0959-8049; 1879-0852; 1879-2995; 0964-1947; 0277-5379Online Volltext: dx.doi.org/
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 25 (2019) Nr. 12, S. 1916 - 1927ISSN: 1546-170X; 1078-8956Online Volltext: dx.doi.org/ (Open Access)
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 141ISSN: 2051-1426Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prognostic factors for pulmonary metastasectomy in malignant melanoma : Size mattersIn: European Journal of Cardio-Thoracic Surgery Jg. 56 (2019) Nr. 6, S. 1104 - 1109ISSN: 1873-734X; 1010-7940; 1567-4258; 1878-3309Online Volltext: dx.doi.org/ (Open Access)
-
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV⁶⁰⁰E inhibition in melanomaIn: European Journal of Cancer Jg. 109 (2019) S. 137 - 153ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology Jg. 30 (2019) Nr. 4, S. 501 - 503ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access)
-
Advanced cutaneous squamous cell carcinoma : A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOGIn: European Journal of Cancer Jg. 96 (2018) S. 34 - 43ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/
-
Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma : A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]In: European Journal of Cancer Jg. 93 (2018) S. 158ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Dose-dependent toxicity of ipilimumab in metastatic melanomaIn: European Journal of Cancer Jg. 95 (2018) S. 104 - 108ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/
-
Fear of cancer progression in patients with stage IA malignant melanomaIn: European Journal of Cancer Care Jg. 27 (2018) Nr. 5,ISSN: 1365-2354; 0961-5423Online Volltext: dx.doi.org/
-
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer Jg. 99 (2018) S. 58 - 65ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
Predictors of quality of life in melanoma patients 4 years after diagnosis : Results of a nationwide cohort study in GermanyIn: Journal of Psychosocial Oncology Jg. 36 (2018) Nr. 6, S. 734 - 753ISSN: 1540-7586; 0734-7332Online Volltext: dx.doi.org/
-
Sebaceous tumours: more than skin deepIn: Gut Jg. 67 (2018) Nr. 11, S. 2045 - 2053ISSN: 0017-5749; 1468-3288Online Volltext: dx.doi.org/
-
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy : A survey in German melanoma patients and their treating physiciansIn: OncoTarget Jg. 9 (2018) Nr. 40, S. 26217 - 26225ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access)
-
The safety and efficacy of dabrafenib and trametinib for the treatment of melanomaIn: Expert Opinion on Drug Safety Jg. 17 (2018) Nr. 1, S. 73 - 87ISSN: 1744-764X; 1474-0338Online Volltext: dx.doi.org/
-
Willingness to pay for a cure of low-risk melanoma patients in GermanyIn: PLoS ONE Jg. 13 (2018) Nr. 5, S. e0197780ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer Jg. 86 (2017) S. 248 - 256ISSN: 1879-2995; 0959-8049; 1879-0852; 0014-2964Online Volltext: dx.doi.org/
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science, IOVS Jg. 58 (2017) Nr. 9, S. 3464 - 3470ISSN: 1552-5783; 0146-0404Online Volltext: dx.doi.org/ (Open Access)
-
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaIn: European Journal of Cancer Jg. 83 (2017) S. 142 - 145ISSN: 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Immunotherapy in melanoma : Recent advances and future directionsIn: European Journal of Surgical Oncology Jg. 43 (2017) Nr. 3, S. 604 - 611ISSN: 1532-2157; 0748-7983Online Volltext: dx.doi.org/
-
Melanoma diagnosed in lesions previously treated by laser therapyIn: The Journal of Dermatology Jg. 44 (2017) Nr. 1, S. 23 - 28ISSN: 1346-8138; 0385-2407Online Volltext: dx.doi.org/
-
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityIn: European Journal of Cancer Jg. 75 (2017) S. 24 - 32ISSN: 1879-2995; 0959-8049; 0014-2964; 1879-0852Online Volltext: dx.doi.org/
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology Jg. 30 (2017) Nr. 7, S. 928 - 939ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget Jg. 8 (2017) Nr. 25, S. 40683 - 40692ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access)
-
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientIn: European Journal of Cancer Jg. 67 (2016) S. 66 - 72ISSN: 0959-8049Online Volltext: dx.doi.org/
-
Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UKIn: European Journal of Dermatology Jg. 26 (2016) Nr. 5, S. 477 - 486ISSN: 1167-1122Online Volltext: dx.doi.org/
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie Jg. 34 (2016) Nr. 1-2, S. 14 - 22ISSN: 0723-6913
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer Jg. 57 (2016) S. 112 - 117ISSN: 0959-8049Online Volltext: dx.doi.org/
-
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyIn: Medicine Jg. 95 (2016) Nr. 46, S. e5375ISSN: 0025-7974; 1536-5964Online Volltext: dx.doi.org/ (Open Access)
-
Actual practice of melanoma follow-up and treatment in Germany : results of a prospective, longitudinal cohort studyIn: British Journal of Dermatology: BJD Jg. 172 (2015) Nr. 6, S. 1646 - 1650ISSN: 1365-2133; 0007-0963; 0366-2845Online Volltext: dx.doi.org/
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget Jg. 6 (2015) Nr. 28, S. 25868 - 25882ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. Suppl. 2, S. 11ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanomaIn: Experimental Dermatology Jg. 24 (2015) Nr. 9, S. 709 - 710ISSN: 1600-0625; 0906-6705Online Volltext: dx.doi.org/
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE Jg. 10 (2015) Nr. 4, S. e0124590ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0118564ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Prospective evaluation of follow-up in melanoma patients in Germany : results of a multicentre and longitudinal studyIn: European Journal of Cancer Jg. 51 (2015) Nr. 5, S. 653 - 667ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Jg. 26 (2015) Nr. 1, S. 250 - 251ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/
-
Segmentally arranged seborrhoeic keratoses with impending atypia and squamous cell carcinoma in an elderly womanIn: British Journal of Dermatology: BJD Jg. 172 (2015) Nr. 6, S. 1642 - 1645ISSN: 1365-2133; 0007-0963; 0366-2845Online Volltext: dx.doi.org/
-
The GERMELATOX DeCOG-trial : The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspectiveIn: European Journal of Cancer Jg. 51 (2015) Nr. Suppl. 3, S. S671 - S672ISSN: 0959-8049Online Volltext: dx.doi.org/
-
Therapie des malignen MelanomsIn: Der Onkologe Jg. 21 (2015) Nr. 10, S. 965 - 974ISSN: 0947-8965Online Volltext: dx.doi.org/
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 747 - 753ISSN: 1569-8041Online Volltext: dx.doi.org/
-
Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rashIn: Journal of the European Academy of Dermatology and Venereology Jg. 28 (2014) Nr. 12, S. 1685 - 1689ISSN: 1468-3083Online Volltext: dx.doi.org/
-
Statin use and its effect on all-cause mortality of melanoma patients : a population-based Dutch cohort studyIn: Cancer Medicine Jg. 3 (2014) Nr. 5, S. 1284 - 1293ISSN: 2045-7634Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute Jg. 106 (2014) Nr. 9,ISSN: 1460-2105; 0027-8874Online Volltext: dx.doi.org/
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 30, S. 3844 - 3845ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research Jg. 19 (2013) Nr. 22, S. 6331 - 6332ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/
-
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomasIn: Clinical Cancer Research Jg. 19 (2013) Nr. 12, S. 3143 - 3152ISSN: 1557-3265; 1557-3265Online Volltext: dx.doi.org/
-
Hautkrebsforschung reloaded : Paradigmenwechsel in der DermatoonkologieIn: Unikate: Berichte aus Forschung und Lehre (2013) Nr. 44: Medizin: 50 Jahre Universitätsklinikum Essen, S. 136 - 143ISBN: 978-3-934359-44-4 ISSN: 0944-6060; 1869-3881Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Intracerebral metastases of malignant melanoma and their recurrences : a clinical analysisIn: Clinical Neurology and Neurosurgery Jg. 115 (2013) Nr. 9, S. 1721 - 1728ISSN: 1872-6968; 0303-8467Online Volltext: dx.doi.org/
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 9, S. 952 - 952ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
β-Blocker use and all-cause mortality of melanoma patients : results from a population-based Dutch cohort studyIn: European Journal of Cancer Jg. 49 (2013) Nr. 18, S. 3863 - 3871ISSN: 0959-8049; 1879-0852; 1879-2995; 0014-2964Online Volltext: dx.doi.org/
-
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 10, S. x104 - x108ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ Online Volltext
-
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 19, S. 2375 - 2383ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Current advances and perspectives in the treatment of advanced melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 5, S. 319 - 325ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Nebenwirkungsmanagement von AfatinibIn: TumorDiagnostik & Therapie Jg. 33 (2012) Nr. 3, S. 154 - 161ISSN: 1439-1279; 1439-1279Online Volltext: dx.doi.org/
-
Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its ManagementIn: Archives of Dermatology Jg. 148 (2012) Nr. 3, S. 357 - 361ISSN: 1538-3652Online Volltext: dx.doi.org/
-
Side effects of systemic oncological therapies in dermatologyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 7, S. 475 - 486ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-upIn: European Journal of Cancer Jg. 47 (2011) Nr. 13, S. 1977 - 1989ISSN: 0964-1947; 1879-0852Online Volltext: dx.doi.org/
-
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen NebenwirkungenIn: Deutsche Medizinische Wochenschrift - DMW Jg. 136 (2011) Nr. 1-2, S. 39 - 44ISSN: 1439-4413; 0012-0472; 1437-5982Online Volltext: dx.doi.org/
-
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Annals of Oncology Jg. 22 (2011) Nr. 7, S. 1667 - 1674ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/
-
Malignant melanoma and Wiedemann-Beckwith syndrome in childhoodIn: Klinische Pädiatrie Jg. 222 (2010) Nr. 6, S. 388 - 390ISSN: 1439-3824Online Volltext: dx.doi.org/
-
PLX4032 : does it keep its promise for metastatic melanoma treatment?In: Expert Opinion on Investigational Drugs Jg. 19 (2010) Nr. 11, S. 1439 - 1449ISSN: 1354-3784; 1744-7658Online Volltext: dx.doi.org/
-
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma : Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementIn: Seminars in Oncology Jg. 37 (2010) Nr. 5, S. 485 - 498ISSN: 0093-7754; 1532-8708Online Volltext: dx.doi.org/
-
Context-Sensitive Modeling of a Standard Operating Procedure for Melanoma Patient Treatment
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 67ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 13 - 14ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Early safety signals from nivolumab in the adjuvant treatment of real-world melanoma patients derived from the German prospective non-interventional study NICO
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 18 - 19ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma : Interim analysis of the ImmunoCobiVem studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9548ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Explainable Radiomics by the example of malignant melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 65 - 66ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 84ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 12 - 13ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Immune Checkpoint Inhibitor (ICI)-associated Pulmonary Manifestations (ICI-LM): Characterization of HRCT and BAL Findings
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie Jg. 76 (2022) Nr. Supplement 1, S. S52ISSN: 0934-8387; 1438-8790Online Volltext: dx.doi.org/ -
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 29 - 30ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 6ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Konzept-basierte Erklärung neuronaler Netze für die Dermatohistopathologie
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 68ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Mitigating Cognitive Bias with Decision Support Systems
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 64ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 88ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9570ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Partielle Remission auf Cemiplimab eines beidseitig Orbitae-infiltrierenden Basalzellkarzinoms des Mittelgesichts
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 44 - 45ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 16 - 17ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomasIn: European Journal of Cancer (EJC) Jg. 173 (2022) Nr. Suppl. 1, S. 20ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 3ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 75 - 76ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Bronchoalveolar lavage fluid (BALF) findings in patients with immune checkpoint inhibitor (ICI)-associated interstitial pneumonia (IP)In: European Respiratory Journal (ERJ) (2021)ISSN: 0903-1936; 1399-3003Online Volltext: dx.doi.org/
-
Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.In: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl., S. 9578 - 9578ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Efficacy of low-dose Total Skin Electron Irradiation followed by oral Maintenance Retinoids in Patients with Mycosis Fungoides and Sezary SyndromeIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 172ISSN: 1439-099X; 0179-7158
-
Image-guided ablative Radiotherapy for Patients with multiple cerebral Metastases using Precision helical IrradiationIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 183ISSN: 1439-099X; 0179-7158
-
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 59 - 60ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
PD-L1-Expression and Mutation Profile in pre-therapeutic Tumor Tissue as Predictors of the Therapeutic Success of PD-1-based Immune Checkpoint Inhibition Therapy in Patients with metastatic Melanoma : Evaluation of the prospective multicentric ADO-Study TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 19ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
PTHrP-induced hypercalcemia Psychosyndrome under Immune Checkpoint Blockade in Patients with penile Squamous Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 23ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 6 - 7ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 31ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Termination of targeted Therapy with BRAF-/MEK Inhibitors after an initial complete Response in Patients with metastatic Melanoma and its clinical Implications : A retrospective, multicenter ADOReg StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 15 - 16ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma : Final results from the dose-finding phase I part of the IMMU-Target trialIn: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 9532 - 9532ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 58 - 59ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Agranulozytose unter Immuncheckpoint‐Blockade : Eine retrospektive, multizentrische AuswertungIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV28ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Apoptotische Gastritis nach Immuncheckpointblockade : Ein typisches histopathologisches MusterIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P12ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Die Extracorporale Photopherese verbessert therapierefraktäre autoimmune Nebenwirkungen nach ImmuncheckpointblockadeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV06ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Die diagnostische Bedeutung der CT-gesteuerten Punktion bei HauttumorpatientenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV49ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Eindrucksvolles und schnelles Therapieansprechen eines metastasierten Adnexkarzinoms unter CemiplimabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV08ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Neoadjuvante Immun‐ und zielgerichtete Therapie bei Melanompatienten im Stadium III BIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV44ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Angiosarkom im Bereich des Capillitium mit der Symptomatik eines Quincke‐Ödems
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 34ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 61 - 62ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 26 - 27ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 49 - 50ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 3ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7 - 8ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Einfluss einer vorangegangenen Radiatio auf den Erfolg einer immunonkologischen Therapie beim metastasierten Melanom – eine retrospektive multizentrische Studie der ADO
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28 - 29ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 3ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 11 - 12ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 38ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Therapieversagen der Immuncheckpoint‐Blockade mit PD1‐Antikörpern bei Patienten mit metastasierten Hauttumorerkrankungen und gleichzeitiger Immunsuppression durch eine Chronisch Lymphatische Leukämie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. Suppl. 3, S. 26 - 27ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
The GERMELATOX DeCOG-trial : German melanoma patients and their attitude toward toxicity during adjuvant interferon treatmentIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. TPS9113ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/